CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 75 enrolled
Drug / intervention
endoscopic mucosal biopsyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02114216
NCT02114216N/ACompleted
CompareCT.gov

Symptomatic Gastroesophageal Reflux Disease is Associated With Increased TRPV1 and PAR2 mRNA Expression Levels in the Esophageal Mucosa

Seoul National University Bundang Hospital·interventional·Posted Apr 15, 2014·Updated May 2, 2016

In Brief

A clinical study evaluating endoscopic mucosal biopsy for Gastro-esophageal Reflux Disease. Completed, enrolled 75 participants across 1 site.

Detailed Summary

Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD). We aimed to evaluate TRPV1 and PAR2 mRNA expression levels in the GERD patients and their relationship with endoscopic findings and reflux symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastro-esophageal Reflux Disease
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 15, 2014
Enrollment StartMar 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.2 years ago

Interventions

endoscopic mucosal biopsyprocedure

endoscopic mucosal biopsy was undertaken for every participant.